Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 21 · below the Ichimoku cloud · RSI 29 (oversold) · MACD below its signal
None of the 29 investors followed here reported a position in FBLG in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a FBLG trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 14, 2026 | Khoja HamidOfficer | Stock Award(Grant) at price 1.68 per share. | 298.5K | $500.00K |
| Mar 3, 2026 | O'Heeron PeterChief Executive Officer | Purchase at price 0.35 - 0.41 per share. | 51.5K | $19.53K |
| Mar 3, 2026 | Khoja HamidOfficer | Purchase at price 0.38 per share. | 30K | $11.40K |
| Mar 1, 2026 | Davis Jason D. CpaChief Financial Officer | Purchase at price 0.41 per share. | 70K | $28.97K |
| Feb 26, 2026 | Garcia Ruben AGeneral Counsel | Purchase at price 0.33 per share. | 40K | $13.06K |
| Dec 10, 2025 | Garcia Ruben AGeneral Counsel | Purchase at price 0.34 per share. | 140K | $47.60K |
| May 26, 2025 | Khoja HamidOfficer | Purchase at price 0.84 per share. | 20K | $16.80K |
| Dec 8, 2024 | O'Heeron PeterChief Executive Officer | — | 100K | — |
| Dec 2, 2024 | O'Heeron PeterChief Executive Officer | — | 50K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 47.6 | -0.9 | -79.9 | 0.0 | -12.1 | -18.3 | -26.2 | 145.7 | -24.4 | -26.9 | −78.9% | ||
| 2025 | -19.5 | -21.7 | -28.6 | 24.4 | -34.8 | -14.8 | 2.4 | -7.4 | -7.5 | -28.0 | -30.3 | -17.9 | −88.8% |
| 2024 | -55.1 | -17.2 | -12.8 | 29.2 | -59.0 | 4.4 | -68.9 | 90.7 | -2.3 | -13.2 | -23.7 | −93.1% |
Buy / hold / sell counts
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.